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Type 2 diabetes (T2D) exists in 25–40% of hospitalized patients.Therapeutic inertia is the delay in the intensification of a treatment
and it is frequent in T2D.The objectives of this study were to detect patients admitted to surgical wards with hyperglycaemia (HH;
fasting glycaemia > 140mg/dL) as well as those with T2D and suboptimal chronic glycaemic control (SCGC) and to assess the
midterm impact of treatmentmodifications indicated at discharge. A total of 412HHpatientswere detected in a period of 18months;
86.6% (357) had a diagnosed T2D.Their preadmittance HbA1c was 7.7± 1.5%; 47% (189) hadHbA1c ≥ 7.4% (SCGC) and weremoved
to the upper step in the therapeutic algorithm at discharge. Another 15 subjects (3.6% of the cohort) had T2D according to their
current HbA1c. Ninety-four of the 189 SCGC patients were evaluated 3–6months later.Their HbA1c before in-hospital-intervention
was 8.6± 1.2% and 7.5± 1.2% at follow-up (𝑃 < 0.004). Active detection of hyperglycaemia in patients admitted in conventional
surgical beds permits the identification of T2D patients with SCGC as well as previously unknown cases. A shift to the upper step
in the therapeutic algorithm at discharge improves this control. Hospitalization is an opportunity to break therapeutic inertia.
1. Introduction
Maintaining good glycaemic control reduces the risk of mi-
crovascular andmacrovascular complications associatedwith
type 2 diabetes (T2D) [1, 2]. However, despite a broad arma-
mentarium of effective glucose-lowering therapies, almost
half of patients with T2D do not achieve globally recognized
blood glucose targets [3, 4]. Between 25 and 40% of patients
admitted in conventional hospitalization beds for other
reasons have T2D. Hyperglycaemia in hospitalized patients,
regardless of the cause, is associated with increasedmorbidity
and mortality and it is known that early diagnosis and treat-
ment improves the general outcomes [5–8].
Therapeutic inertia (TI) is the delay in the onset or inten-
sification of a required treatment [9]. TI exists in a consider-
able percentage of patients with T2D, being reported in about
50% of cases [10, 11]. Hospitalization for other causes than
diabetes could be a good opportunity to detect patients with
T2D and poor glycaemic control and thus overcome TI, and,
moreover, it may allow detecting unknown cases. Surgical
departments of general hospitals usually have a very high
prevalence of T2D patients.
The objectives of this prospective study were to set up a
programme for active detection and treatment of hypergly-
caemic patients during the admission in conventional surgi-
cal beds, to identify patients with previously known T2D that
have a suboptimal chronic glycaemic control (SCGC) and to
Hindawi Publishing Corporation
International Journal of Endocrinology
Volume 2015, Article ID 381415, 5 pages
http://dx.doi.org/10.1155/2015/381415
2 International Journal of Endocrinology
evaluate the impact of treatment modifications indicated at
the time of hospital discharge on the glycaemic control at
midterm.
2. Material and Methods
This new intervention programme started in May 2012 in
Hospital Germans Trias i Pujol, a tertiary referral hospital
affiliated to the Universitat Autònoma of Barcelona, Catalo-
nia, Spain.The Centre has 509 beds, with 353 of them in con-
ventional hospitalization and 150 of those devoted to surgical
services. The protocol has been progressively implemented
in five surgical hospitalization departments (orthopaedics
and traumatology, vascular surgery, general and digestive
surgery, neurosurgery, and urology) in the last two years,
and a pre- and postintervention assessment were planned in
order to evaluate their efficacy. Admitted patients in these
departments are noncritically ill ones and hyperglycaemia
was defined as premeal blood glucose greater than 140mg/dL,
following the specific recommendations of ADA for man-
agement of hyperglycaemia in hospitalized patients [12–
14]. Detection of hyperglycaemia in our centre uses an
electronic warning message by which a glycaemic threshold
of 140mg/dL is automatically generated from admittance
analyses for all the patients of surgical wards and then
communicated to the Endocrinology Service by midday. The
generated list of patients is then revised by a team of senior
and junior residents and by a nurse and supervised by a
senior staff member. The electronic clinical histories of these
patients and their recent HbA
1c levels are evaluated; if there
is no <3 months data regarding HbA
1c, a new measurement
is performed with the recent blood sample from the present
hospital stay, following the recommendations of the ADA
[14]. HbA
1c was measured in blood samples with ethylene-
diaminetetraacetic acid (EDTA) by high-performance liquid
chromatographic (HPLC) using a fully automated Adams
Menarini HI-AUTO A1c 8160 analyzer manufactured by
Arkray (Kyoto, Japan) with an interassay coefficient of vari-
ation of 1.8 and 1.5% at HbA
1c levels of 4.8 and 9.0%, respec-
tively (reference range: 4–5.8%). This method is a cation
exchange HPLC method certified by the NGSP (National
Glycohemoglobin Standardization Program) of traceability
to the Diabetes Control and Complications Trial Reference
Method (DCCT).
Hyperglycaemic patients were categorized into one of the
following four groups: (A) controlled T2D: T2D previously
known and HbA
1c < 7.4%; (B) T2D: previously known with
SCGC as defined by a HbA
1c ≥ 7.4%; (C) T2D: not previ-
ously known as defined by hyperglycaemia > 140mg/dL and
HbA
1c ≥ 6.5%; (D) undetermined hyperglycaemic status, as
defined by hyperglycaemia > 140mg/dL and HbA
1c < 6.5%.
During hospital stay, all patients were treated following
the institutional protocol of control of hyperglycaemia con-
sisting of a basal-bolus insulin therapy designed according to
the level of hyperglycaemia and the fasting condition required
for the perioperative period. When patients were discharged,
those in group (B) (HbA
1c ≥ 7.4%) received a reassessment of
their nutritional plan and were moved to an upper step of the
therapeutic algorithm, following the recommendations by
the Spanish societies of endocrinology and diabetes and the
EASD/ADA [15, 16]. Patients in group (A) (well controlled
diabetic patients) remained under the same treatment as
that before their hospital admission. New diagnosis of T2D
patients (group (C)) was initiated in diabetes treatment
according to the HbA
1c level and clinical judgement by the
consultant diabetologist team. All patients, regardless of the
group, received the recommendation to make a follow-up
appointment by their primary care team at 3–6 months of
the hospital discharge. All treatments changes were specified
in a highlighted manner in the discharge reports. In those
patients with SCGC (group (B)) HbA
1c was determined
again between three and six months after hospital discharge
and evaluated according to the usual criteria by their primary
care team. We compared these with previous results by con-
sulting the electronic clinical history.
Continuous variables were expressed as mean standard
deviations (SD) or median (interquartile range) and cate-
gorical variables as frequency and/or percentage. Differences
between groups were assessed by the Student’s 𝑡-test or the
nonparametric Mann-Whitney 𝑈 test, as appropriated. A 𝑃
value less than 0.05 was considered statistically significant.
Categorical variables were compared with 𝜒2 test. All statis-
tical analyses were performed using the Statistical Package
for Social Science (SPSS, Chicago, IL, USA) for personal
computers, version 12.0 (SPSS).
3. Results
Four hundred and twelve hyperglycaemic patients were
detected during the first 18 months after initiation of the pro-
gramme. Of the 412 patients, 193 (47%) had an acute illness
and the rest (219; 53%) had been planning program admis-
sion. The most common reasons for admission in patients
with an acute processwere bone fractures,mainly femur, arte-
rial peripheral ischemia, cholecystitis, pancreatitis and other
abdominal infectious processes, hemorrhagic stroke, and
urological infections.Themost frequent diagnoses of patients
with scheduled hospital admissionwere chronic degenerative
arthropathy, arterial stenosis, lesions that needed to be ampu-
tated, neoplasias of the digestive tract and the central nervous
system, spinal disc herniation, and tumors of the kidney and
prostate. Of the total 412 patients, 357 (86.6%) had previous
known T2D (groups A and B) and 145 were women (40.6%),
with a mean age of 69.7 ± 10.4 years, T2D evolution of 9 ±
9.5 years, and HbA
1c of 7.6% ± 1.4. From the 357 patients with
knownT2D, 168 (52.9%)were under good control (group (A),
HbA
1c 6.5%± 0.5).They had amean age of 70.4 ± 11 years and
a T2D evolution of 6.5 ± 6.1 years.The remaining 189 patients
(47%, group (B), HbA
1c 8.6% ± 1.3) had a mean age of 69.2 ±
9.8 years and a T2D evolution of 10.9 ± 10.8 years. Patients in
group (B) had a longer evolution of the T2D in comparison
to those of group (A) and their HbA
1c was also higher (𝑃 <
0.001 for both). Fifteen patients had newly detected T2D
(group (C)), corresponding to 3.6% of the total cohort, and in
40 patients the hyperglycaemic status was found in conjunc-
tion with an HbA
1c < 6.5% (group (D)). Mean age in group
(C) was 68.8 ± 12.7 years and in group (D) 60.7 ± 18.3 years.
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Table 1: Data of 94 out of 189 patients (group (B)) whose therapeutic changes were performed andwere reassessed 3–6months after discharge.
𝑁 Women % Age (years) DM evolution (years) HbA1c PRE (%) HbA1c POST (%)
94 37 (39.4) 68.94 ± 9.89 12.44 ± 11.88 8.66 ± 1.27 7.50 ± 1.25∗
∗
𝑃 < 0.004.




Patients in group (B) were moved to the upper step of
the therapeutic algorithm [15, 16] at the time of hospital
discharge. This action included the initiation of insulin
therapy in 28 out of 357 patients with known T2D (14.8%).
Ninety-four of the 189 patients from those whose therapeutic
changes were performed have been assessed 3–6months after
discharge by consulting the primary care electronic clinical
history. Their HbA
1c improved significantly (preadmission
or in-hospital HbA
1c 8.6% ± 1.27 and after discharge 7.5% ±
1.25, 𝑃 < 0.004). These data are shown in Table 1. In the
remaining 95 patients with SCGC, 45 showed no HbA
1c in
the clinical history due to a lack of scheduled follow-up visit
after discharge and in the other 55 the follow-up visit was still
not performed, as the time elapsed from discharge was less
than 6 months.
4. Discussion
Recently, different diabetes medical societies have made
specific recommendations for the care of diabetic patients
regarding their glycaemic control when they are in hospital
for any cause not specifically related to diabetes. Moreover,
there is a general feeling that a certain delay exists in detecting
diabetic patients and initiating the specific protocol for hyper-
glycaemia control while the patient is hospitalized, in partic-
ular in those admitted to surgical wards [17]. These scientific
societies have proposed to take action against this situation by
implementing both active detection and adequate treatment
of diabetic patients when they are admitted to the hospital
irrespective of the cause of admission [5]. Diabetes is present
in a proportion as high as one-third to half of patients in
community hospitals, a figure that will grow steadily in the
near future in industrialized countries due to the increasing
prevalence of diabetes, mostly related to ageing. The possi-
bility to have automatic warnings that indicate the presence
of the diabetic condition in a given patient provided from
different hospital check points allows gaining time when
classifying which patients require more prompt attention.
Our tertiary hospital has an electronic clinical history shared
with primary care physicians; thus current and past relevant
information from a specific patient can travel across the
health system on a real time basis.
Our protocol allowed us to detect 357 known T2D
patients among those admitted to conventional beds of sur-
gical services. Most of these would probably not have been
considered as potential diabetologic consultations by their
physicians in charge, as assessed by the comparison of the
historical number of calls received from the specific surgical
services included in the programme and the number of
patients detected by the current programme. These patients
are noncritically ill and a very heterogenic group. The
challenge of defining the goals of antihyperglycaemic therapy
arises from their heterogeneitymainly in relation to the aging
process along with their diverse clinical characteristics. As
a group, they should be treated as elderly diabetic patients.
Therefore, it was considered that patients with HbA
1c < 7.4%
were controlled [18]. Almost half of the patients detected
(47%) had a previous SCGC at the time of hospital admission
according to HbA
1c values. Some studies conducted in
different geographical areas in Spain have confirmed a similar
percentage of T2Dpatientswith poor glycaemic control when
primary care databases are evaluated [19–21]. These figures
may be even higher when complex diabetic patients with
active comorbidities andmostly followed at tertiary hospitals
are concerned. Overall, the present study demonstrates that
a substantial number of patients show a significant—either
clinical or statistical—improvement in the glycaemic control
at short- and midterm after active detection, evaluation, and
modification of the therapeutic programme for every specific
case. Consequently, we observed a 1% mean decrease of
HbA
1c, thus reaching the recommended 7.5% HbA1c value
for this age group of patients. Additionally, 3.6% of the total
cohort corresponded to new cases; thus our programme
allowed an early treatment in these particular patients or at
least did not further delay the diagnosis of T2D.
Therapeutic inertia (TI) is defined as the situation by
which a given patient requiring a next step treatment modal-
ity usually with higher complexity does not receive the
appropriate treatment. TI seems to be present approximately
in one-third to 40% [22, 23] or even more [24, 25] of T2D
patients with poor glycaemic control, especially those treated
only with lifestyle changes or oral monotherapy, and also in
older subjects. Assessing the true prevalence of TI is difficult
and it should be noted that the methodology used to obtain
these figures is heterogeneous.Moreover, TI is not the same as
clinical inertia (CI) which includes not only the responsibility
of the physician at the time of escalation in the therapeutic
algorithm towards more complex treatment modalities but
also the position of the patient, in which he/she voluntarily
decides not to follow the therapy proposed by the diabetes
team. In this regard, CI requires educational and emotional
support, while TI requiresmedical training and support from
expertise. Finally, the evaluation of HbA
1c as the indicator of
TI should also be refined according to individual goal conve-
nient for every patient, mostly related to concurrent diabetes
complications and age. Therefore, a given patient may have
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a convenient HbA
1c 8% value if he/she has major comorbidi-
ties and/or is very old and frail. However, this same value
is inadequate for younger subjects with no apparent active
comorbidities and relatively short duration of the disease.
In a recent multicentre, retrospective study of patients
with poorly controlled diabetes and at least one hospital-
ization [26], less than a quarter received a change in their
diabetes therapy upon discharge, and nearly one-third had no
subsequent follow-up visit scheduled, suggesting widespread
TI. In our cohort, a substantial number of subjects, around a
quarter, did not have a primary care scheduled visit 6 months
after discharge. This approach of controlling the whole
process after discharge by temporal assessment of the shared
electronic clinical histories also allows the implementation of
rescue actions towards the reinclusion of patients lost in the
follow-up by means of phone calls and other ways of contact.
The overall approach could, therefore, increase the quality of
care for T2D.
The implementation of an active detection programme
and treatment of hyperglycaemia in patients admitted in
conventional surgical beds, such as the one presented in this
study, is, therefore, feasible in the habitual clinical practice
andnecessary for a substantial proportion of patients.We also
demonstrated that themodification of the previous treatment
to an upper step in the diabetes therapeutic algorithm
together with the personalization of recommendations in
patients with type 2 diabetes is able to obtain a significant
improvement in the glycaemic control, at least at midterm.
5. Conclusions
Admission in a conventional surgical bed for any cause is
a clear opportunity for overcoming therapeutic inertia and
improving glycaemic control in patients with type 2 diabetes.
We, therefore, propose the implementation of an active detec-
tion and treatment programme of hyperglycaemia, as we
describe here, in all community and tertiary hospitals.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
The authors want to thank Mr. Costas Pilounis (Novo-Nor-
disk) for his support in setting up this programme and, also,
the assistance of Mr. Gary Shivel for paper review. This work
was done in part with the support of a grant fromNovo-Nor-
disk.
References
[1] A. Patel, S. MacMahon, J. Chalmers et al., “Intensive blood
glucose control and vascular outcomes in patients with type 2
diabetes,” The New England Journal of Medicine, vol. 358, pp.
2560–2572, 2008.
[2] P. Gæde, H. Lund-Andersen, H.-H. Parving, and O. Pedersen,
“Effect of a multifactorial intervention on mortality in type 2
diabetes,”The New England Journal of Medicine, vol. 358, no. 6,
pp. 580–591, 2008.
[3] T. J. Hoerger, J. E. Segel, E. W. Gregg, and J. B. Saaddine, “Is
glycemic control improving in U.S. adults?” Diabetes Care, vol.
31, no. 1, pp. 81–86, 2008.
[4] M. F. B. Braga, A. Casanova, H. Teoh et al., “Treatment gaps in
the management of cardiovascular risk factors in patients with
type 2 diabetes in Canada,” Canadian Journal of Cardiology, vol.
26, no. 6, pp. 297–302, 2010.
[5] G. E. Umpierrez, S. D. Isaacs, N. Bazargan, X. You, L. M.Thaler,
and A. E. Kitabchi, “Hyperglycemia: an independent marker
of in-hospital mortality in patients with undiagnosed diabetes,”
Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 3,
pp. 978–982, 2002.
[6] S. E. Inzucchi, “Management of hyperglycemia in the hospital
setting,” The New England Journal of Medicine, vol. 355, no. 18,
pp. 1903–1911, 2006.
[7] A. Bruno, D. Gregori, A. Caropreso, F. Lazzarato, M. Petrinco,
and E. Pagano, “Normal glucose values are associated with a
lower risk of mortality in hospitalized patients,” Diabetes Care,
vol. 31, no. 11, pp. 2209–2210, 2008.
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